Evolus, Inc.

US$6.80As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:EOLSHealthcare
Country USA
PE (Fwd) •••
TSR 9Y CAGR (6.40%)
Div yield —
ROE —
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 1.34
PE TTM —
TSR TTM 5.34%
Mkt cap US$450.4M
ROIC (8.66%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$8.31
22.13%
(75.71%)
Hold 6|2|5|2|1
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.15
0.17
0.18
0.17
29.63%
24.99%
28.17%
14.94%
Revenue$M
19.37
18.83
18.32
19.23
(2.96%)
(6.52%)
(6.86%)
(2.83%)
Peers (US$450.4M)
Cap (US$)
PE
450.8M
38.23x
Capital
TTM
5Y
10Y
Leveragex
0.732
(0.266)
(0.267)
EBIT/Intx
11.43
0.136
0.147
Own earn%
(3.28)
(108.95)
(96.79)
Sh yield%
28.06
24.82
26.95
Owners
Insiders/Inst%
13.79
31.43
Short interest%
3.11
SBC / revenue%
0.36
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
3
Op margin range%
8–12
$1 testx
—
Incr. ROIC%
3